The Claim
Among adults without diabetes or cardiovascular disease prescribed GLP-1 receptor agonists for weight management, the risk of myocardial infarction, stroke, or heart failure does not differ statistically significantly between those using semaglutide and those using liraglutide over one year of follow-up.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults without diabetes or heart disease who are taking GLP-1 receptor agonists to lose weight, the rates of heart attack, stroke, and heart failure are the same for those taking semaglutide compared to those taking liraglutide after one year.
See the scientific wording
Among adults without diabetes or cardiovascular disease prescribed GLP-1 receptor agonists for weight management, there is no statistically significant difference in the risk of myocardial infarction, stroke, or heart failure between those using semaglutide and those using liraglutide over one year of follow-up.
Both drugs activate the same receptors in the body at similar levels, which lowers blood sugar, reduces fat storage, and decreases blood pressure. These changes keep the heart and blood vessels from being damaged, so neither drug leads to more heart attacks, strokes, or heart failure than the other.
What the research says
1 studyThe study found that semaglutide and liraglutide were equally likely to prevent heart attacks, strokes, or heart failure in people using them for weight loss over one year—neither was better than the other.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.